US FDA calls for heart/diabetes risk warnings for class of prostate cancer drugs

21 October 2010

The US Food and Drug Administration yesterday asked manufacturers to add new warnings to labeling of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs primarily used to treat men with prostate cancer.

The drugs, are sold under brand names that include Abbott Laboratories' ( NYSE: ABT) Lupron (leuprolide acetate), AstraZeneca’s (LSE: AZN) Zoladex (goserelin acetate, Sanofi Aventis' (Euronext: SAN) Eligard (leuprolide acetate), Pfizer's (NYSE: PFE) Synarel (nafarelin) and Watson Pharmaceuticals’ NYSE: WPI) Trelstar (triptorelin pamoate).

The warnings would alert patients and their health care professionals to the potential risk of heart disease and diabetes in men treated with these medications.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK